Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):413–416. doi: 10.1038/bjc.1992.84

Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer.

Y Maehara 1, K Sugimachi 1, M Akagi 1, T Kakegawa 1, H Shimazu 1, M Tomita 1
PMCID: PMC1977594  PMID: 1558796

Abstract

We studied the effect of early postoperative chemotherapy, including 5-fluorouracil (5-FU) for 5 days for patients with gastric cancer following noncurative resection. The study was prospectively randomised and controlled, and 162 (87.1%) of 186 were eligible candidates for statistical assessment. Patients randomised to group A received therapy that is used widely to treat patients with gastric cancer in Japan; mitomycin C (MMC), OK-432, UFT and PSK. Patients randomised to group B received the same drugs given to group A plus 5-FU bolus injections for 5 days, beginning on postoperative day 2. There were no differences in prognostic factors and doses of the drugs prescribed, except for 5-FU. There was no difference in the toxicity rate between the groups. Generalised Wilcoxon test revealed a P value of 0.169, and the 50% survival rate improved 1.4-fold in patients with gastric cancer treated with early postoperative chemotherapy of MMC, OK-432 plus 5-FU injection.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boku T., Nakane Y., Okusa T., Hirozane N., Imabayashi N., Hioki K., Yamamoto M. Strategy for lymphadenectomy of gastric cancer. Surgery. 1989 May;105(5):585–592. [PubMed] [Google Scholar]
  2. Engstrom P. F., Lavin P. T., Douglass H. O., Jr, Brunner K. W. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer. 1985 May 1;55(9):1868–1873. doi: 10.1002/1097-0142(19850501)55:9<1868::aid-cncr2820550904>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  3. Fielding J. W., Fagg S. L., Jones B. G., Ellis D., Hockey M. S., Minawa A., Brookes V. S., Craven J. L., Mason M. C., Timothy A. An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group. World J Surg. 1983 May;7(3):390–399. doi: 10.1007/BF01658089. [DOI] [PubMed] [Google Scholar]
  4. Fraile R. J., Baker L. H., Buroker T. R., Horwitz J., Vaitkevicius V. K. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res. 1980 Jul;40(7):2223–2228. [PubMed] [Google Scholar]
  5. Gunduz N., Fisher B., Saffer E. A. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979 Oct;39(10):3861–3865. [PubMed] [Google Scholar]
  6. Haller D. G. Chemotherapy in gastrointestinal malignancies. Semin Oncol. 1988 Jun;15(3 Suppl 4):50–64. [PubMed] [Google Scholar]
  7. Higgins G. A., Amadeo J. H., Smith D. E., Humphrey E. W., Keehn R. J. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer. 1983 Sep 15;52(6):1105–1112. doi: 10.1002/1097-0142(19830915)52:6<1105::aid-cncr2820520629>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  8. Inokuchi K., Hattori T., Taguchi T., Abe O., Ogawa N. Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years. Cancer. 1984 Jun 1;53(11):2393–2397. doi: 10.1002/1097-0142(19840601)53:11<2393::aid-cncr2820531104>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  9. Kano T., Kumashiro R., Tamada R., Kodama Y., Inokuchi K. Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach. Jpn J Surg. 1981;11(4):291–296. doi: 10.1007/BF02468770. [DOI] [PubMed] [Google Scholar]
  10. Kano T., Tamada R., Abe Y., Hiramoto Y., Notsuka T., Shiraishi M., Inoue F., Kumashiro R., Kodama Y., Inokuchi K. Postoperative long-term cancer chemotherapy (PLCC) extends life-span of non-curatively resected patients with stage IV gastric cancer. Jpn J Surg. 1982;12(3):203–207. doi: 10.1007/BF02469588. [DOI] [PubMed] [Google Scholar]
  11. Kodama Y., Sugimachi K., Soejima K., Matsusaka T., Inokuchi K. Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg. 1981 Mar;5(2):241–248. doi: 10.1007/BF01658301. [DOI] [PubMed] [Google Scholar]
  12. Maehara Y., Kusumoto T., Kusumoto H., Anai H., Sakaguchi Y., Kido Y., Okamura T., Korenaga D., Sugimachi K. 5-Fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase. Cancer. 1989 May 1;63(9):1693–1696. doi: 10.1002/1097-0142(19900501)63:9<1693::aid-cncr2820630908>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  13. Maehara Y., Moriguchi S., Sakaguchi Y., Emi Y., Kohnoe S., Tsujitani S., Sugimachi K. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol. 1990 Nov;45(3):169–172. doi: 10.1002/jso.2930450307. [DOI] [PubMed] [Google Scholar]
  14. Maehara Y., Sugimachi K., Akagi M., Kakegawa T., Shimazu H., Tomita M. Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. Cancer Res. 1990 Jul 1;50(13):3952–3955. [PubMed] [Google Scholar]
  15. Maehara Y., Watanabe A., Kakeji Y., Baba H., Kohnoe S., Sugimachi K. Postgastrectomy prescription of mitomycin C and UFT for patients with stage IV gastric carcinoma. Am J Surg. 1990 Sep;160(3):242–244. doi: 10.1016/s0002-9610(06)80015-2. [DOI] [PubMed] [Google Scholar]
  16. Ota K., Taguchi T., Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 1988;22(4):333–338. [PubMed] [Google Scholar]
  17. Seifert P., Baker L. H., Reed M. L., Vaitkevicius V. K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975 Jul;36(1):123–128. doi: 10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  18. Tsukagoshi S., Hashimoto Y., Fujii G., Kobayashi H., Nomoto K., Orita K. Krestin (PSK). Cancer Treat Rev. 1984 Jun;11(2):131–155. doi: 10.1016/0305-7372(84)90005-7. [DOI] [PubMed] [Google Scholar]
  19. Uchida A., Hoshino T. Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer. 1980 Feb;45(3):476–483. doi: 10.1002/1097-0142(19800201)45:3<476::aid-cncr2820450311>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES